National Dementia Diagnostics Laboratory
NATA/RCPA accreditation number 19256
Specimen Reception and NDDL over Public Holidays:
The National Dementia Diagnostics Laboratory (NDDL) is located at the Florey Institute of Neuroscience and Mental Health, in conjunction with the University of Melbourne. The NDDL closes for Victorian and National Public Holidays. Please hold all diagnostic samples at -20oC during affected periods. Contact us for further information about Specimen Reception at the NDDL.
Cerebrospinal Fluid Alzheimer Disease Screen
Abeta1-42, Tau, Phospho-Tau
The Cerebrospinal Fluid (CSF) Alzheimer Disease Screen is an ante-mortem diagnostic test that detects alterations in the levels of biomarker proteins, specifically amyloid Abeta42, total-tau and phospho-tau, which are believed to be directly related to the pathophysiology of Alzheimer's disease (AD). Based on international experience, these CSF biomarkers offer approximately 80-90% sensitivity and specificity for clinically overt AD and valuable prognostic information in persons with amnestic mild cognitive impairment (1). The recommendations detailed for CSF handling align with the consensus statement issued by the Alzheimer's Biomarker Standardisation Initiative (2,3).
- must be collected directly into the polypropylene tube – Please download the sample collection sheet (Version 5.0, updated May 2017)
- must be accompanied with the Specimen Data Sheet – Please download the CSF Alzheimer's disease Screen specimen data sheet (Version 8.0, updated June 2017)
Diagnostic Testing Fees (non-rebatable)
AD screen (three proteins) $190; any two proteins $150; any single protein $100
The test is run fortnightly, except insufficient samples.
1. Li et al. Alzheimer disease normative CSF biomarkers validated in PET Aβ characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimer’s Dis. 2015; 48:175–187; Hulstaet et al. Neurology 1999; 52:1555; Hansson et al., Lancet Neurol, 2006;5(3):228-34; Buchhave et al. Arch Gen Psychiatry 2012; 69: 98-106;
2. Vanderstichele et al. Alzheimer's and Dementia 2012; 8:65-73.
3. This laboratory is a member of the Alzheimer's Association QC program.
Phone: (03) 9035 7243
Facsimile: (03) 9035 8768
Dr Qiao-Xin Li
National Dementia Diagnostics Laboratory
Florey Institute of Neuroscience and Mental Health
Kenneth Myer Building / Melbourne Brain Centre
30 Royal Parade (corner of Genetics Lane)
Enter via Gate 11, rear loading dock
Parkville Victoria 3010
Cerebrospinal Fluid Creutzfeldt Jakob disease Screen
14-3-3 and Tau Protein Test
The 14-3-3 and tau proteins are non-specific, ante-mortem markers of central nervous system neuronal injury or death. Based on international experience in carefully selected patients, a positive result has approximately 80-90% sensitivity and specificity for sporadic Creutzfeldt-Jakob disease. While most often concordant, the two protein biomarkers should be viewed as complementary. False positives are recognized in various disease processes; for example encephalitis, encephalopathies and recent cerebral infarcts. Consequently, unselected sampling is less reliable as screening for a possible diagnosis of sporadic CJD.
The NDDL/Australian National Creutzfeldt-Jakob disease Registry (ANCJDR) is the only NATA accredited diagnostic laboratory in Australia that provides 14-3-3 and Tau CSF protein testing.
For specific details regarding the specimen requirements and reception, please refer to the main ANCJDR website or contact the ANCJDR main office on Phone: 61 3 8344 1949 or Email: firstname.lastname@example.org
Scientists in the Neurodegeneration division interrogate how neurones live, die and can be rescued to improve brain function in degenerative conditions such as Parkinson’s and Motor Neuron Diseases. There is no effective treatment for Motor Neurone Disease and the incidence of Parkinson’s Disease is rising alarmingly in our aging community. Gene abnormalities, energy deprivation, toxic rubbish accumulation and inflammation all contribute to a toxic environment for brain cells. Our teams study these events in animal models and cultured cells, with a view to translating knowledge into new therapies for human patients.